BioStart in Cincinnati will close its wet lab for medical device and pharma products but will continue to provide support for biomedical start-ups in the area, according to a report by MedCity.
As more drug and device startups outsource development work, demand for wet lab space has declined, said BioStart President Carol Frankenstein. Currently, 18 companies are occupying 65 percent of BioStart's available space.
The company currently has $500,000 in funding to parcel out. Since it started in 1996, BioStart has helped 125 med-tech companies launch and raise a total of $180 million.
Read the MedCity report on BioStart.
Related Articles on Medical Device Start-ups:
Nevro Raises $58M to Prepare Spinal Cord Stimulator for U.S. Launch
Device Publication Names Five Most Innovative CEOs
Report Calls for Less Complexity in Medical Device Design